<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122571">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01506947</url>
  </required_header>
  <id_info>
    <org_study_id>W12-645</org_study_id>
    <nct_id>NCT01506947</nct_id>
  </id_info>
  <brief_title>A Prospective Open-Label, Non-randomised, Single-arm, Pilot Clinical Study Evaluating the Effect of PTH Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients</brief_title>
  <official_title>A Prospective Open-Label Pilot Clinical Study Evaluating the Effect of PTH Lowering on Erythropoietin Consumption in Calcitriol-Resistant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a prospective open label, non-randomised, single-arm, pilot clinical
      study evaluating the Effect of PTH Lowering on erythropoietin consumption in calcitriol
      resistant patients with stage 5 chronic kidney disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in erythropoietin (EPO) consumption in patients</measure>
    <time_frame>6 months</time_frame>
    <description>EPO dosage required to keep serum haemoglobin levels between 10 to 11,5 g/dl will be recorded.The recordings and blood tests to assess the haemoglobin levels will be conducted monthly.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in the quality of life scores of patients with chronic kidney disease (CKD)</measure>
    <time_frame>6 months</time_frame>
    <description>The quality of life of patients will be evaluated by using the SF-36 Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the changes in commonly assessed biochemical parameters for bone and mineral metabolism (intact parathyroid hormone [iPTH], Calcium [Ca], Phosphorus [P], Vitamin B12, Folic acid ,Alkaline Phosphatase [ALP]) during treatment with paricalcitol.</measure>
    <time_frame>6 months</time_frame>
    <description>Blood tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in High-sensitivity C-Reactive Protein (hsCRP) and Fibroblast growth factor 23 (FGF-23) values</measure>
    <time_frame>6 months</time_frame>
    <description>Blood tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse Events-The number of participants with adverse events will be reported as a measure of Safety.</measure>
    <time_frame>6 months</time_frame>
    <description>The investigators will monitor each subject for clinical and lab evidence of adverse events on a routine basis through out the study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Moderate to Severe Secondary Hyperparathyroidism</condition>
  <condition>Stage 5 Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Paricalcitol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <description>Paricalcitol will be administered by intravenous route, and will be initiated in patients with a intact parathyroid hormone (iPTH) level &gt;500 pg/mL, and the starting dose will be calculated according to the following formula; paricalcitol (µg) for each dialysis session= intact parathyroid hormone (iPTH) (pg/mL)/120.</description>
    <arm_group_label>Paricalcitol</arm_group_label>
    <other_name>ABT-358</other_name>
    <other_name>Zemplar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A subject will only be included if all the following entry criteria are met:

          -  Patients &gt;=18 years of age

          -  Stage 5 CKD patients receiving hemodialysis and with moderate to severe secondary
             hyperparathyroidism (SHPT) receiving hemodialysis

          -  Patients with anemia receiving EPO therapy with iron repletion; Transferrin
             saturation (TSAT) &gt; 20% and Ferritin levels &gt; 200 ng/mL and requiring treatment with
             erythropoietin (EPO)

          -  Patients with Vitamin B levels &gt; LLN and Folic acid levels &gt; LLN

          -  SATPatients with Vitamin B levels &gt; LLN and Folic acid levels &gt; LLN

          -  Patients treated only with intravenous calcitriol for at least 6 months

          -  Patients with serum iPTH level &gt; 500 pg/mL

          -  Patients with Ca . PO4 product &lt; 65 mg2/dL2

          -  Patients willing to sign &quot;written informed consents&quot; before participating in any the
             study related activity.

          -  Patients with Ca levels &lt;6.5 mg/dL and P levels &lt;11.2 mg/dL

        Exclusion Criteria:

        A subject will be excluded from the study if he/she meets any of the following criteria:

          -  Patients who have known hypersensitivity and/or toxicity to vitamin D metabolites
             and/or to paricalcitol and/or to other product ingredients.

          -  Patients who have participated in a clinical study within the last month.

          -  Patients whose previous concomitant medication and laboratory data for 6 months prior
             to the baseline visit are not available.

          -  Patients with known contraindication to selective Vitamin D receptor activators
             (VDRAs) according to the SmPC.

          -  Pregnancy, Female patients pregnant, breast-feeding or planning a pregnancy within
             next 6 months after enrollment. Sexually active female patients not accepting
             appropriate contraceptive methods during the course of the study will also be
             excluded.

          -  Hypertensive and diabetic patients who are not on an optimal and steady medication
             regimen for more than 30 days.

          -  Patients with microcytic (MCV &lt; 80 fL) and macrocytic (MCV&gt; 100 fL) anemia at
             screening baseline that may be caused by diseases such as Micros- Fe Deficiency,
             Thalassemias, Anemia of Chronic Disease, Copper Deficiency, Zn poisoning,
             Sideroblastic Anemia, Macros-ethanol abuse, myelodysplastic syndromes, acute myeloid
             leukemias, reticulocytosis, drug induced anemia, liver disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmut Gücük, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 49202</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 83894</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130949</name>
      <address>
        <city>Istanbul</city>
        <zip>34147</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 131209</name>
      <address>
        <city>Istanbul</city>
        <zip>34200</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 83895</name>
      <address>
        <city>Istanbul</city>
        <zip>34371</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 83896</name>
      <address>
        <city>Istanbul</city>
        <zip>34730</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 83893</name>
      <address>
        <city>Istanbul</city>
        <zip>34890</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 13, 2016</lastchanged_date>
  <firstreceived_date>December 28, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>Secondary hyperparathyroidism,</keyword>
  <keyword>Chronic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
